HC Wainwright restated their buy rating on shares of ChromaDex (NASDAQ:CDXC – Free Report) in a research report released on Monday morning,Benzinga reports. They currently have a $11.00 target price ...
Stock analysts at HC Wainwright raised their Q2 2025 EPS estimates for shares of OPKO Health in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst Y.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback